Clinical trials explorer

Interim analysis

Personalized mRNA neoantigen vaccine — resected PDAC (phase I)

Pancreas

Pancreatic mRNA vaccine phase I; early immune/follow-up signals — not standard care.

Registry checked: 2026-10-29

Interim analysis

Daraxonrasib (RMC-6236) — RAS(ON) inhibitor in advanced RAS-mutant solid tumors

Pancreas · Multiple / solid tumors

RAS(ON) inhibitor phase I/II early activity; phase III (RASolute 302) is separate.

Registry checked: 2026-10-29

MRTX1133 — KRAS G12D-targeted inhibitor (early clinical)

Pancreas · Multiple / solid tumors

KRAS G12D MRTX1133 phase I terminated early — no efficacy claim.

Registry checked: 2026-10-29

Elironrasib + daraxonrasib — RAS(ON) combination (phase I/II)

Pancreas · Multiple / solid tumors

Early-phase RAS(ON) combo; separate from RASolute 302 / RMC-6236-001.

Registry checked: 2026-10-29

Interim analysis

ELI-002 — amphiphile peptide vaccine in KRAS-mutant solid tumors (phase I)

Pancreas · Multiple / solid tumors

Off-the-shelf amphiphile peptide+CpG vaccine; not part of the personalized mRNA neoantigen area.

Registry checked: 2026-10-29

WaKING — Wnt + checkpoint inhibition in gastric cancer

Gastric / esophageal

Early Wnt+IO gastric; mechanism separate from SPOTLIGHT/KEYNOTE-585.

Registry checked: 2026-10-29

SX-682 + nivolumab — RAS-mutant MSS unresectable CRC

Colon · Rectum

Early phase; hypothesis to sensitize MSS RAS+ CRC to IO — separate from MSI IO.

Registry checked: 2026-10-29

ARMADA — armored CAR-T (DLL3+ cancers, phase I)

Multiple / solid tumors

Phase I armored CAR-T; recruiting. Solid-tumor translation early — not GI standard.

Registry checked: 2026-10-29